Compared topical ocular olopatadine 0.1% (Patanol) and loteprednol etabonate 0.2% (Alrex) in an allergen challenge model.
Novack
Gary D
GD
D000730:Androstadienes / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D003990:Dibenzoxepins / Q000627:therapeutic use*; D006801:Humans; D000069559:Loteprednol Etabonate; D000069605:Olopatadine Hydrochloride; D009883:Ophthalmic Solutions / Q000627:therapeutic use*
D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D003990:Dibenzoxepins; D009883:Ophthalmic Solutions; D000069605:Olopatadine Hydrochloride; D000069559:Loteprednol Etabonate